Cargando…

Epigenetics in Breast Cancer Therapy—New Strategies and Future Nanomedicine Perspectives

SIMPLE SUMMARY: Despite advances in cancer treatment, difficult-to-treat tumor subtypes remain a challenge. New multidisciplinary approaches can help overcome current obstacles posed by tumor heterogeneity, activation and enrichment of cancer stem cells, and acquired drug resistance development. Epi...

Descripción completa

Detalles Bibliográficos
Autores principales: Buocikova, Verona, Rios-Mondragon, Ivan, Pilalis, Eleftherios, Chatziioannou, Aristotelis, Miklikova, Svetlana, Mego, Michal, Pajuste, Karlis, Rucins, Martins, Yamani, Naouale El, Longhin, Eleonora Marta, Sobolev, Arkadij, Freixanet, Muriel, Puntes, Victor, Plotniece, Aiva, Dusinska, Maria, Cimpan, Mihaela Roxana, Gabelova, Alena, Smolkova, Bozena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7761669/
https://www.ncbi.nlm.nih.gov/pubmed/33287297
http://dx.doi.org/10.3390/cancers12123622
_version_ 1783627622511542272
author Buocikova, Verona
Rios-Mondragon, Ivan
Pilalis, Eleftherios
Chatziioannou, Aristotelis
Miklikova, Svetlana
Mego, Michal
Pajuste, Karlis
Rucins, Martins
Yamani, Naouale El
Longhin, Eleonora Marta
Sobolev, Arkadij
Freixanet, Muriel
Puntes, Victor
Plotniece, Aiva
Dusinska, Maria
Cimpan, Mihaela Roxana
Gabelova, Alena
Smolkova, Bozena
author_facet Buocikova, Verona
Rios-Mondragon, Ivan
Pilalis, Eleftherios
Chatziioannou, Aristotelis
Miklikova, Svetlana
Mego, Michal
Pajuste, Karlis
Rucins, Martins
Yamani, Naouale El
Longhin, Eleonora Marta
Sobolev, Arkadij
Freixanet, Muriel
Puntes, Victor
Plotniece, Aiva
Dusinska, Maria
Cimpan, Mihaela Roxana
Gabelova, Alena
Smolkova, Bozena
author_sort Buocikova, Verona
collection PubMed
description SIMPLE SUMMARY: Despite advances in cancer treatment, difficult-to-treat tumor subtypes remain a challenge. New multidisciplinary approaches can help overcome current obstacles posed by tumor heterogeneity, activation and enrichment of cancer stem cells, and acquired drug resistance development. Epigenome modulation, currently unsuccessful in solid tumors due to epigenetic drug instability, toxicity, and off-target effects, might be enabled by implementing nano-based delivery strategies aiming to improve breast cancer patient outcomes. ABSTRACT: Epigenetic dysregulation has been recognized as a critical factor contributing to the development of resistance against standard chemotherapy and to breast cancer progression via epithelial-to-mesenchymal transition. Although the efficacy of the first-generation epigenetic drugs (epi-drugs) in solid tumor management has been disappointing, there is an increasing body of evidence showing that epigenome modulation, in synergy with other therapeutic approaches, could play an important role in cancer treatment, reversing acquired therapy resistance. However, the epigenetic therapy of solid malignancies is not straightforward. The emergence of nanotechnologies applied to medicine has brought new opportunities to advance the targeted delivery of epi-drugs while improving their stability and solubility, and minimizing off-target effects. Furthermore, the omics technologies, as powerful molecular epidemiology screening tools, enable new diagnostic and prognostic epigenetic biomarker identification, allowing for patient stratification and tailored management. In combination with new-generation epi-drugs, nanomedicine can help to overcome low therapeutic efficacy in treatment-resistant tumors. This review provides an overview of ongoing clinical trials focusing on combination therapies employing epi-drugs for breast cancer treatment and summarizes the latest nano-based targeted delivery approaches for epi-drugs. Moreover, it highlights the current limitations and obstacles associated with applying these experimental strategies in the clinics.
format Online
Article
Text
id pubmed-7761669
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-77616692020-12-26 Epigenetics in Breast Cancer Therapy—New Strategies and Future Nanomedicine Perspectives Buocikova, Verona Rios-Mondragon, Ivan Pilalis, Eleftherios Chatziioannou, Aristotelis Miklikova, Svetlana Mego, Michal Pajuste, Karlis Rucins, Martins Yamani, Naouale El Longhin, Eleonora Marta Sobolev, Arkadij Freixanet, Muriel Puntes, Victor Plotniece, Aiva Dusinska, Maria Cimpan, Mihaela Roxana Gabelova, Alena Smolkova, Bozena Cancers (Basel) Review SIMPLE SUMMARY: Despite advances in cancer treatment, difficult-to-treat tumor subtypes remain a challenge. New multidisciplinary approaches can help overcome current obstacles posed by tumor heterogeneity, activation and enrichment of cancer stem cells, and acquired drug resistance development. Epigenome modulation, currently unsuccessful in solid tumors due to epigenetic drug instability, toxicity, and off-target effects, might be enabled by implementing nano-based delivery strategies aiming to improve breast cancer patient outcomes. ABSTRACT: Epigenetic dysregulation has been recognized as a critical factor contributing to the development of resistance against standard chemotherapy and to breast cancer progression via epithelial-to-mesenchymal transition. Although the efficacy of the first-generation epigenetic drugs (epi-drugs) in solid tumor management has been disappointing, there is an increasing body of evidence showing that epigenome modulation, in synergy with other therapeutic approaches, could play an important role in cancer treatment, reversing acquired therapy resistance. However, the epigenetic therapy of solid malignancies is not straightforward. The emergence of nanotechnologies applied to medicine has brought new opportunities to advance the targeted delivery of epi-drugs while improving their stability and solubility, and minimizing off-target effects. Furthermore, the omics technologies, as powerful molecular epidemiology screening tools, enable new diagnostic and prognostic epigenetic biomarker identification, allowing for patient stratification and tailored management. In combination with new-generation epi-drugs, nanomedicine can help to overcome low therapeutic efficacy in treatment-resistant tumors. This review provides an overview of ongoing clinical trials focusing on combination therapies employing epi-drugs for breast cancer treatment and summarizes the latest nano-based targeted delivery approaches for epi-drugs. Moreover, it highlights the current limitations and obstacles associated with applying these experimental strategies in the clinics. MDPI 2020-12-03 /pmc/articles/PMC7761669/ /pubmed/33287297 http://dx.doi.org/10.3390/cancers12123622 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Buocikova, Verona
Rios-Mondragon, Ivan
Pilalis, Eleftherios
Chatziioannou, Aristotelis
Miklikova, Svetlana
Mego, Michal
Pajuste, Karlis
Rucins, Martins
Yamani, Naouale El
Longhin, Eleonora Marta
Sobolev, Arkadij
Freixanet, Muriel
Puntes, Victor
Plotniece, Aiva
Dusinska, Maria
Cimpan, Mihaela Roxana
Gabelova, Alena
Smolkova, Bozena
Epigenetics in Breast Cancer Therapy—New Strategies and Future Nanomedicine Perspectives
title Epigenetics in Breast Cancer Therapy—New Strategies and Future Nanomedicine Perspectives
title_full Epigenetics in Breast Cancer Therapy—New Strategies and Future Nanomedicine Perspectives
title_fullStr Epigenetics in Breast Cancer Therapy—New Strategies and Future Nanomedicine Perspectives
title_full_unstemmed Epigenetics in Breast Cancer Therapy—New Strategies and Future Nanomedicine Perspectives
title_short Epigenetics in Breast Cancer Therapy—New Strategies and Future Nanomedicine Perspectives
title_sort epigenetics in breast cancer therapy—new strategies and future nanomedicine perspectives
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7761669/
https://www.ncbi.nlm.nih.gov/pubmed/33287297
http://dx.doi.org/10.3390/cancers12123622
work_keys_str_mv AT buocikovaverona epigeneticsinbreastcancertherapynewstrategiesandfuturenanomedicineperspectives
AT riosmondragonivan epigeneticsinbreastcancertherapynewstrategiesandfuturenanomedicineperspectives
AT pilaliseleftherios epigeneticsinbreastcancertherapynewstrategiesandfuturenanomedicineperspectives
AT chatziioannouaristotelis epigeneticsinbreastcancertherapynewstrategiesandfuturenanomedicineperspectives
AT miklikovasvetlana epigeneticsinbreastcancertherapynewstrategiesandfuturenanomedicineperspectives
AT megomichal epigeneticsinbreastcancertherapynewstrategiesandfuturenanomedicineperspectives
AT pajustekarlis epigeneticsinbreastcancertherapynewstrategiesandfuturenanomedicineperspectives
AT rucinsmartins epigeneticsinbreastcancertherapynewstrategiesandfuturenanomedicineperspectives
AT yamaninaoualeel epigeneticsinbreastcancertherapynewstrategiesandfuturenanomedicineperspectives
AT longhineleonoramarta epigeneticsinbreastcancertherapynewstrategiesandfuturenanomedicineperspectives
AT sobolevarkadij epigeneticsinbreastcancertherapynewstrategiesandfuturenanomedicineperspectives
AT freixanetmuriel epigeneticsinbreastcancertherapynewstrategiesandfuturenanomedicineperspectives
AT puntesvictor epigeneticsinbreastcancertherapynewstrategiesandfuturenanomedicineperspectives
AT plotnieceaiva epigeneticsinbreastcancertherapynewstrategiesandfuturenanomedicineperspectives
AT dusinskamaria epigeneticsinbreastcancertherapynewstrategiesandfuturenanomedicineperspectives
AT cimpanmihaelaroxana epigeneticsinbreastcancertherapynewstrategiesandfuturenanomedicineperspectives
AT gabelovaalena epigeneticsinbreastcancertherapynewstrategiesandfuturenanomedicineperspectives
AT smolkovabozena epigeneticsinbreastcancertherapynewstrategiesandfuturenanomedicineperspectives